Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Metronomic PLOF in Gastric Cancer
NCT06054906Phase 2Recruiting
- Sponsor
- Huashan Hospital
- Start
- Oct 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in gastric cancer (GC), sponsored by Huashan Hospital. Primary endpoints: Pathologic Complete Response at 6 weeks and Major Pathologic Response at 6 weeks. Started Oct 2023; status: recruiting.
02
Drugs
sintilimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06054906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06054906.